Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R31 | P59538 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CA4 | P22748 | 2/20 | 0.70 |
| ▸ | DPP4 | P27487 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CA7 | P43166 | 2/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.70 |
| ▸ | TTR | P02766 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641776 | 1.00 | TAS2R31 (0.72) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL773766 | 1.00 | TAS2R31 (0.72) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| Alpinetin SCHEMBL30741428 | 0.93 | CYP1A1 (0.80) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| Alpinetin SCHEMBL29844118 | 0.93 | CYP1A1 (0.80) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| Alpinetin SCHEMBL29580312 | 0.93 | CYP1A1 (0.80) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL26118588 | 0.91 | CYP3A4 (0.65) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL1460821 | 0.91 | HSD17B10 (0.76) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL11128429 | 0.91 | HSD17B10 (0.76) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL1460823 | 0.91 | HSD17B10 (0.76) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 | |
| SCHEMBL29722583 | 0.91 | HSD17B10 (0.76) | TAS2R31CYP19A1CYP3A4CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005740-A | Recombinant microorganism for high-level synthesis of polyphenol compounds and application thereof | 中国科学院天津工业生物技术研究所 | 2025-05-16 | — | — | CN | claimed |
| CN-120005740-A | Recombinant microorganism for high-level synthesis of polyphenol compounds and application thereof | 中国科学院天津工业生物技术研究所 | 2025-05-16 | — | — | CN | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | TAS2R31 3954/4885CYP19A1 119/4885CYP3A4 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.